Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

Findings Support Development for Chronic Pain Indications

LA JOLLA, Calif., Feb. 11 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, was safe and well-tolerated in healthy male and female subjects when dosed once daily for five consecutive days.

"The successful completion of this Phase I trial demonstrating the safety and tolerability of NGX426 when dosed over multiple days provides support for pursuing a Phase II program in chronic indications," said Ev Graham, Chief Executive Officer of TorreyPines. "Combined with the positive results from our recently completed Phase I study of NGX426 in a capsaicin induced pain model, we are very encouraged about the potential for NGX426 to treat both acute and chronic pain conditions."

The Phase I double-blind, placebo-controlled trial enrolled 20 healthy male and female subjects in sequential, dose-escalating cohorts. Subjects received once-daily oral doses of either 90 mg or 150 mg of NGX426 or placebo for five consecutive days, approximating exposure under steady-state pharmacokinetic conditions. Overall, NGX426 was well-tolerated. There were no dose-limiting adverse events or discontinuations from the study and reported adverse events were generally mild and transient.

NGX426, an ester prodrug, is an oral form of tezampanel, TorreyPines most advanced product candidate. Pharmacokinetic analyses from two Phase I studies confirmed that when given to humans, NGX426 is rapidly converted to tezampanel, the active moiety. To date, six Phase II, double-blind, placebo-controlled trials have demonstrated that tezampanel, administered either subcutaneously or intravenously, was more effective than placebo in relieving pain across migraine, nocic
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company, is pleased to announce that ... injector (RCI-02) have been locked.  Prototypes for industrial ... prepare for an application for CE mark clearance ... in 2016. (Photo: ...
(Date:7/29/2015)... ... July 29, 2015 , ... Available in select spas ... Bi-Gel, a nighttime-specific product that targets fat cells for extreme contouring action. During ... enter fat cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks ...
(Date:7/29/2015)... ... ... Nearly everyone has heard of the potential of stem cells to treat ... of these cells is teeth—baby teeth that come loose during childhood, wisdom teeth extracted ... room for braces. These potent stem cells exist in the dental pulp of ...
(Date:7/28/2015)... VILLAGE, Nev. , July 28, 2015  PDL ... ) today announced that the Company will release its ... June 30, 2015, on Wednesday, August 5, 2015, after ... and webcast that day at 4:30 p.m. Eastern Time ... to the call will be available via the webcast ...
Breaking Biology Technology:RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... , EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - ... treatment of multiple sclerosis (MS), today announced that the Company ... Award" at the 4th Annual Scrip Awards held in London, ... development agreement granting Eli Lilly and Company (Lilly) exclusive worldwide ...
... http://www.myngle.com ), the global language platform, has just ... Europe Unlimited,s European Venture Summit,(EVS) ( http://www.e-unlimited.com/events/p200245/overview.asp ). ... is a showcase for the most promising Information ... from all over Europe to meet,and present themselves ...
... Mass., Dec. 11 Pressure BioSciences, Inc. (Nasdaq: ... International ("Omni") today announced that they have entered into ... the terms of the Agreement, the companies will: (1) ... information; (2) co-promote certain products at industry trade shows ...
Cached Biology Technology:BioMS Medical recognized at Scrip Awards 2008 2Myngle Best ICT Company at the European Ventures Summit 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 3Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 4Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 5
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
(Date:7/27/2015)... ANGELES , July 27, 2015   ... evidence- and experience-based clinical improvement solutions, today announced ... solution is now available on Android smartphones and ... inpatient and post-care organizations can use ZynxCarebook to ... same patient,s condition, streamline care transitions to other ...
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... New Rochelle, NY, July 25, 2012A novel approach to gene ... of a natural disease-fighting protein could offer a solution to ... a 2- to 3-fold increase in production of a protein ... article published Instant Online in Human Gene Therapy , ...
... in life almost certainly have consequences for later cognitive ... infants cannot be used as laboratory subjects. Rodney ... for studying infant brain development. "Assistant professor Ryan Dilger ... as a model of human brain and cognitive development ...
... Central the open access publisher is proud to present ... and Genome Biology the third annual Beyond ... Boston, USA from 27-29 September 2012. Following ... on next-generation sequencing and other new technologies, informatics tools ...
Cached Biology News:New gene therapy strategy boosts levels of deficient protein in Friedreich's ataxia 2Piglets in mazes provide insights into human cognitive development 2Piglets in mazes provide insights into human cognitive development 3Piglets in mazes provide insights into human cognitive development 4
... Micro Kit provides a fast and simple ... of protein samples. The kit is based ... resin as an ion exchanger. Salts such ... poor affinities for Norgens resin and are ...
... Multipeptide Kit, designed for use with ... variety of amyloid peptides more straightforward ... Clinical neuroscience proteomics applications - Monitor ... Correlate beta-amyloid peptide levels with disease ...
... chamber assembly (1 each) Components (chamber ... user guide plastic tweezersChambers are stainless ... and reused. The chamber is designed for ... and all custom oligo microarrays, in conjunction ...
... variant: With the macro- ... by Hoagland and Arnon ... Formulated to contain 1.6 ... per liter of medium. ...
Biology Products: